Canan Koksal
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Canan Koksal has a total of 51 co-authors. Here are the top co-authors by number of shared publications:
- Nazmiye Donmez Kesen
Division of Medical Physics, Istanbul University Oncology Institute, Istanbul, Turkey
8 shared publications Hatice Bilge
Division of Medical Physics, Istanbul University Oncology Institute, Istanbul, Turkey
7 shared publications- Kamuran Ibis
Department of Radiation Oncology, Institute of Oncology, Istanbul University, 34093 Istanbul, Türkiye
7 shared publications - Ugur Akbas
Division of Medical Physics, Istanbul University Oncology Institute, Istanbul, Turkey
7 shared publications Sule Karaman
3 shared publicationsLeyla Suncak
2 shared publications
Latest Publications
- Open Access
A Comparative Study of Five Target Volume Definitions for Radiotherapy in Glioblastoma Multiforme
Background and Objectives: This study aimed to compare target volumes and organ-at-risk (OAR) doses using five different volume definitions in radiotherapy (RT) planning of patients with glioblastoma multiforme (GBM). Materials and Methods: Rigid image fusion was performed using simulation computed tomography and postoperative magnetic resonance imaging scans of 20 patients with GBM. Volumetric modulated arc therapy (VMAT) plans were generated according to three two-phase protocols—American Brain Tumor Consortium (ABTC), North Central Cancer Treatment Group/Alliance (NCCTG/Alliance), and Radiation Therapy Oncology Group/NRG (RTOG/NRG)—and two single-phase protocols—European Organisation for Research and Treatment of Cancer (EORTC) and European Society for Radiotherapy and Oncology–European Association of Neuro-Oncology (ESTRO/EANO)—each delivering a total dose of 60 Gy. OARs and dose constraints were evaluated. Statistical analysis was performed using the paired sample t-test. Results: The ESTRO/EANO volume had the smallest median PTV overall (p < 0.001). The lowest brain-PTV Dmean in the initial phase was observed in the ABTC group, followed closely by ESTRO/EANO (p < 0.001). Among boost volumes, the ABTC volume was the smallest, and the median brain-PTV Dmean was lowest in the ESTRO/EANO volume. ESTRO/EANO provided the lowest doses for contralateral and ipsilateral cochlea Dmean, brainstem D1cc, and contralateral lens Dmax. Notably, both EORTC and ESTRO/EANO plans maintained OAR doses within acceptable constraints, with ESTRO/EANO achieving the most consistently minimised exposure. Conclusions: Reduced irradiated brain volume, acceptable OAR preservation and practical applicability, the use of ESTRO-EANO and EORTC target volumes in radiotherapy of glioblastoma multiforme may provide dosimetric advantages that require further validation in clinical outcome studies.
Open AccessA Comparative Study of Five Target Volume Definitions for Radiotherapy in Glioblastoma Multiforme
Background and Objectives: This study aimed to compare target volumes and organ-at-risk (OAR) doses using five different volume definitions in radiotherapy (RT) planning of patients with glioblastoma multiforme (GBM). Materials and Methods: Rigid image fusion was performed using simulation computed tomography and postoperative magnetic resonance imaging scans of 20 patients with GBM. Volumetric modulated arc therapy (VMAT) plans were generated according to three two-phase protocols—American Brain Tumor Consortium (ABTC), North Central Cancer Treatment Group/Alliance (NCCTG/Alliance), and Radiation Therapy Oncology Group/NRG (RTOG/NRG)—and two single-phase protocols—European Organisation for Research and Treatment of Cancer (EORTC) and European Society for Radiotherapy and Oncology–European Association of Neuro-Oncology (ESTRO/EANO)—each delivering a total dose of 60 Gy. OARs and dose constraints were evaluated. Statistical analysis was performed using the paired sample t-test. Results: The ESTRO/EANO volume had the smallest median PTV overall (p < 0.001). The lowest brain-PTV Dmean in the initial phase was observed in the ABTC group, followed closely by ESTRO/EANO (p < 0.001). Among boost volumes, the ABTC volume was the smallest, and the median brain-PTV Dmean was lowest in the ESTRO/EANO volume. ESTRO/EANO provided the lowest doses for contralateral and ipsilateral cochlea Dmean, brainstem D1cc, and contralateral lens Dmax. Notably, both EORTC and ESTRO/EANO plans maintained OAR doses within acceptable constraints, with ESTRO/EANO achieving the most consistently minimised exposure. Conclusions: Reduced irradiated brain volume, acceptable OAR preservation and practical applicability, the use of ESTRO-EANO and EORTC target volumes in radiotherapy of glioblastoma multiforme may provide dosimetric advantages that require further validation in clinical outcome studies.
- Open Access
- 25 August 2025
- Published by MDPI AG in Diagnostics
- Vol. 15 (17) , 2142
Prognostic Significance of Nomogram and T-Score in Locally Advanced Cervical Cancer Patients Treated with Curative Chemoradiotherapy and Image-Guided Brachytherapy: A Single-Center Retrospective Study
Objective: To investigate the survival prediction probability of the nomogram from retro-EMBRACE and the T-score in patients with locally advanced cervical cancer (LACC). Materials and Methods: A total of 204 patients with LACC who underwent curative chemoradiotherapy and brachytherapy (BT) between 2010 and 2021 were included in our single-center retrospective study. Clinical records, examinations, and magnetic resonance images (MRI) before and after external beam radiotherapy (EBRT) were retrospectively reviewed to obtain information on age, tumor size, parametrial involvement, ureteral involvement, bladder invasion, uterine involvement, high-risk clinical target volume at the first brachytherapy application, lymph node involvement, vaginal involvement, recurrence, metastasis, and last follow-up. The 5-year overall survival probabilities of the patients were determined by nomogram. T-score was calculated separately at diagnosis (TSD) and brachytherapy (TSBT), and their effects on local recurrence-free survival, disease-free survival, and overall survival were analyzed. Results: The median age was 52 (29–89). The 5-year survival rate of the patients was calculated to be 90.18%. The median nomogram’s survival estimate for 60 months was 70.35% (20.9–87.1). The median TSD and TSBT were 5.5 (1–16) and 1 (0–6), respectively. According to the multivariate Cox regression models, TSD (HR = 1.203, 95% CI 1.021–1.417, p = 0.024) was significantly associated with local recurrence-free survival. Conclusions: This study demonstrated that the nomogram’s predictions for 60-month overall survival are underestimates. Prognosis can be estimated using the TSD, which can be easily obtained with a clinical examination and detailed MRI examination.
- 25 August 2025
- Published by MDPI AG in Diagnostics
- Vol. 15 (17) , 2142
Open AccessPrognostic Significance of Nomogram and T-Score in Locally Advanced Cervical Cancer Patients Treated with Curative Chemoradiotherapy and Image-Guided Brachytherapy: A Single-Center Retrospective Study
Objective: To investigate the survival prediction probability of the nomogram from retro-EMBRACE and the T-score in patients with locally advanced cervical cancer (LACC). Materials and Methods: A total of 204 patients with LACC who underwent curative chemoradiotherapy and brachytherapy (BT) between 2010 and 2021 were included in our single-center retrospective study. Clinical records, examinations, and magnetic resonance images (MRI) before and after external beam radiotherapy (EBRT) were retrospectively reviewed to obtain information on age, tumor size, parametrial involvement, ureteral involvement, bladder invasion, uterine involvement, high-risk clinical target volume at the first brachytherapy application, lymph node involvement, vaginal involvement, recurrence, metastasis, and last follow-up. The 5-year overall survival probabilities of the patients were determined by nomogram. T-score was calculated separately at diagnosis (TSD) and brachytherapy (TSBT), and their effects on local recurrence-free survival, disease-free survival, and overall survival were analyzed. Results: The median age was 52 (29–89). The 5-year survival rate of the patients was calculated to be 90.18%. The median nomogram’s survival estimate for 60 months was 70.35% (20.9–87.1). The median TSD and TSBT were 5.5 (1–16) and 1 (0–6), respectively. According to the multivariate Cox regression models, TSD (HR = 1.203, 95% CI 1.021–1.417, p = 0.024) was significantly associated with local recurrence-free survival. Conclusions: This study demonstrated that the nomogram’s predictions for 60-month overall survival are underestimates. Prognosis can be estimated using the TSD, which can be easily obtained with a clinical examination and detailed MRI examination.
- 1 January 2024
- Published by LookUs Bilisim A.S. in Turkish Journal of Oncology
- Vol. 39 (1) , 19-26
Comparison of Measured and Calculated Halcyon 3.0 Beam Data
- 1 January 2024
- Published by LookUs Bilisim A.S. in Turkish Journal of Oncology
- Vol. 39 (1) , 19-26
Comparison of Measured and Calculated Halcyon 3.0 Beam Data
- Open Access
- 1 January 2022
- Published by RAD Centre
Dose comparison of total body irradiation in different treatment planning system algorithms
- 1 January 2022
- Published by RAD Centre
Open AccessDose comparison of total body irradiation in different treatment planning system algorithms
- Open Access
- 1 January 2021
- Published by Sievert Association
IMPACT OF INTERMEDIATE DOSE CALCULATION MODULE ON THORACIC ESOPHAGUS CANCER RADIOTHERAPY PLANNING
- 1 January 2021
- Published by Sievert Association
Open AccessIMPACT OF INTERMEDIATE DOSE CALCULATION MODULE ON THORACIC ESOPHAGUS CANCER RADIOTHERAPY PLANNING
- 1 January 2021
- Published by Elsevier in Medical Dosimetry
- Vol. 46 (2) , 136-142
Investigation of approaches for internal target volume definition using 4-dimensional computed tomography in stereotactic body radiotherapy of lung cancer
- 1 January 2021
- Published by Elsevier in Medical Dosimetry
- Vol. 46 (2) , 136-142
Investigation of approaches for internal target volume definition using 4-dimensional computed tomography in stereotactic body radiotherapy of lung cancer
- 31 May 2020
- Published by Suleyman Demirel Universitesi Fen Edebiyat Fakultesi Fen Dergisi in Süleyman Demirel Üniversitesi Fen Edebiyat Fakültesi Fen Dergisi
- Vol. 15 (1) , 130-139
Dosimetric Comparison of 3D-CRT, IMRT, IMAT and Helical Tomotherapy for Thoracic Esophageal Carcinoma
In this study, we compared the dose-volume parameters for treatment of thoracic esophageal cancer with treatment plans for 3D-CRT, IMRT, IMAT and HT. 15 thoracic esophagus patients who were treated in our clinic between 2017-2018 years were selected. PTV volumes were between 205 and 445.4 cc with an average of 355.2 cc. 3D-CRT, IMRT, IMAT and HT radiotherapy plans were created for each patient using the same contours and the same dose planning prescription. Total dose of 50.4 Gy for all patients was planed with 180 cGy dose per a fraction in total 28 fractions. For PTV; when the four treatment techniques were compared, HI values were 3D-CRT 0.84 ± 0.0, IMRT 0.57 ± 0.05, IMAT 0.06 ± 0.013, HT 0.08 ± 0.03 (p <0.05). CI values were found for 3D-CRT as 1.84 ± 0.2, for IMRT as 1.25 ± 0.05, for IMAT as 1.19 ± 0.04, for HT as 1.2 ± 0.06 (p <0.05). IMRT and IMAT techniques provided better OAR protection compared to other techniques in all lung and heart comparisons. The lowest doses for Dmax and D1% of Spinal Cord were provided by HT technique. We found that IMRT, IMAT and HT techniques have lower critical organ doses than 3D-CRT technique for treating torasic esophageal cancer. Considering the current evidence of the relationship between radiation-induced cardiac toxicity in the literature and the dose-volume parameters after treatment for esophageal cancer in our study, we can say that dose plans are better for IMRT and IMAT plans than 3D-CRT and HT in terms of lung and heart doses.
- 31 May 2020
- Published by Suleyman Demirel Universitesi Fen Edebiyat Fakultesi Fen Dergisi in Süleyman Demirel Üniversitesi Fen Edebiyat Fakültesi Fen Dergisi
- Vol. 15 (1) , 130-139
Dosimetric Comparison of 3D-CRT, IMRT, IMAT and Helical Tomotherapy for Thoracic Esophageal Carcinoma
In this study, we compared the dose-volume parameters for treatment of thoracic esophageal cancer with treatment plans for 3D-CRT, IMRT, IMAT and HT. 15 thoracic esophagus patients who were treated in our clinic between 2017-2018 years were selected. PTV volumes were between 205 and 445.4 cc with an average of 355.2 cc. 3D-CRT, IMRT, IMAT and HT radiotherapy plans were created for each patient using the same contours and the same dose planning prescription. Total dose of 50.4 Gy for all patients was planed with 180 cGy dose per a fraction in total 28 fractions. For PTV; when the four treatment techniques were compared, HI values were 3D-CRT 0.84 ± 0.0, IMRT 0.57 ± 0.05, IMAT 0.06 ± 0.013, HT 0.08 ± 0.03 (p <0.05). CI values were found for 3D-CRT as 1.84 ± 0.2, for IMRT as 1.25 ± 0.05, for IMAT as 1.19 ± 0.04, for HT as 1.2 ± 0.06 (p <0.05). IMRT and IMAT techniques provided better OAR protection compared to other techniques in all lung and heart comparisons. The lowest doses for Dmax and D1% of Spinal Cord were provided by HT technique. We found that IMRT, IMAT and HT techniques have lower critical organ doses than 3D-CRT technique for treating torasic esophageal cancer. Considering the current evidence of the relationship between radiation-induced cardiac toxicity in the literature and the dose-volume parameters after treatment for esophageal cancer in our study, we can say that dose plans are better for IMRT and IMAT plans than 3D-CRT and HT in terms of lung and heart doses.
- 1 January 2019
- Published by Galenos Yayinevi in Istanbul Medical Journal
- Vol. 20 (1) , 49-53
Changing Trends in Radiotherapy for Glioblastoma Multiforme and Effects on Normal Tissue Doses
- 1 January 2019
- Published by Galenos Yayinevi in Istanbul Medical Journal
- Vol. 20 (1) , 49-53
Changing Trends in Radiotherapy for Glioblastoma Multiforme and Effects on Normal Tissue Doses